Latest Market Research News

Pureprofile Limited has agreed to acquire CRNRSTONE, an established Australian qualitative research firm, for $700,000 in cash, enhancing its market research capabilities and expected to be earnings accretive from year one.

Botanix Pharmaceuticals has launched a A$45 million capital raising to support the expansion of its dermatology product Sofdra®, while negotiating to reduce active pharmaceutical ingredient costs by up to 40%. The raising includes a two-tranche placement and a security purchase plan, with options offered to investors.

Breville Group Limited has reported a record half-year revenue of AUD 1.1 billion, overcoming US tariff challenges through strategic manufacturing shifts and robust product innovation. The company’s steady profitability and geographic expansion signal a confident growth trajectory.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

PainChek has secured FDA-regulated medical device status, enabling US Remote Therapeutic Monitoring reimbursement and opening a major US growth avenue. The company targets musculoskeletal pain management in non-verbal dementia patients, a largely underserved market.

Pureprofile has reported record first-half FY26 results, driven by strong international expansion and AI-powered platform growth, prompting an upgrade to its full-year revenue guidance.

Botanix Pharmaceuticals reported a robust 28% increase in net revenue for Sofdra in Q2 FY26, driven by a 24% rise in prescriptions and a growing US sales team. The company maintains a strong cash position while navigating higher operating costs.

Anteris Technologies Global Corp. has launched a $230 million equity offering alongside an $84 million private placement with Medtronic’s subsidiary, aiming to accelerate clinical trials and scale manufacturing of its innovative DurAVR Transcatheter Heart Valve.

Osteopore Limited has partnered with DKSH Malaysia in a five-year agreement to distribute its innovative dental products, aiming to capture significant growth in Malaysia’s guided bone regeneration sector.

Clarity Pharmaceuticals has responded to ASX queries clarifying the timing and materiality of its SAR-bisFAP data presentation, denying the information was price sensitive despite a notable share price rise.

Cazaly Resources has addressed a sharp rise in its share price and trading volume, attributing the movement to strong gold and silver prices alongside a recent independent research report.